Enterprise Value
70.96M
Cash
47.98M
Avg Qtr Burn
-3.941M
Short % of Float
2.50%
Insider Ownership
9.46%
Institutional Own.
32.25%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Rezafungin Details Infectious disease, Fungal infections, Candidemia | Approved Quarterly sales | |
Rezafungin Details Infectious disease, Fungal infections | Phase 3 Data readout | |
CD388 (DFCs) Details Infectious disease, Influenza | Phase 2a Data readout |